
Bristol Myers, Charles River join Series A funding for iVexSol
Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical. iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of…… Click here to view original post… […]